UK innovation strategy is changing, with a move away from across-the-board generic support, and a return to picking winners and promoting particular technologies
They are some of the largest spenders on research. But now, as pharmaceutical companies look to external collaboration and in-licensed products to fuel innovation, the internal R&D operation is having to justify the return on investment for the first time
Entrepreneurs from the United Kingdom gained the most nominations at this year’s Academic Enterprise Awards. Three UK spin-outs are among the top 12 chosen to go through to final awards in Brussels on 21 February, 2012.
The UK may have used its veto on treaty change, but it will support increased spending on R&D from 2014 – 2020, as proposed in Horizon 2020. Cutting agriculture subsidies could pay for this, Business Minister Vince Cable tells Science|Business
A roundtable discussion, with EU Innovation Lecturer Henry Chesbrough and leading practitioners, on the practical challenges and opportunities of open innovation in Europe
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.